UPB - Upstream Bio, Inc.

6.1
-0.200   -3.279%

Share volume: 212,237
Last Updated: 04-04-2025
Pharmaceutical Products/Pharmaceutical Preparations: -0.02%

PREVIOUS CLOSE
CHG
CHG%
$6.30
-0.20
-0.03%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
18%
Profitability 0%
Dept financing 50%
Liquidity 50%
Performance 20%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-6.01%
1 Month
-31.77%
3 Months
-62.28%
6 Months
-70.11%
1 Year
-70.11%
2 Year
-70.11%
Key data
Stock price
$6.10
P/E Ratio 
N/A
DAY RANGE
$5.59 - $6.12
EPS 
N/A
52 WEEK RANGE
$5.59 - $22.37
52 WEEK CHANGE
-$70.11
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
04-15-2025
BETA 
1.45
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$226,198
AVERAGE 30 VOLUME 
$236,444
Company detail
CEO: E. Rand Sutherland
Region: US
Website: upstreambio.com
Employees: 0
IPO year: 2024
Issue type:
Market: NASDAQ
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

We are a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. Our principal corporate office is located at 890 Winter Street, Suite 200, Waltham, MA 02451. We have one subsidiary, Upstream Bio Securities Corporation, formed in November 2021 under the laws of the Commonwealth of Massachusetts.

Recent news
loading